{"nctId":"NCT00459667","briefTitle":"BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose","startDateStruct":{"date":"2007-05"},"conditions":["Multiple Sclerosis, Relapsing-Remitting"],"count":1420,"armGroups":[{"label":"IFNB-1b 500 mcg","type":"EXPERIMENTAL","interventionNames":["Drug: Interferon beta-1b (Betaseron, BAY86-5046)"]},{"label":"IFNB-1b 250 mcg","type":"EXPERIMENTAL","interventionNames":["Drug: Interferon beta-1b (Betaseron, BAY86-5046)"]},{"label":"IFNB-1b 250 mcg*","type":"EXPERIMENTAL","interventionNames":["Drug: Interferon beta-1b (Betaseron, BAY86-5046)"]}],"interventions":[{"name":"Interferon beta-1b (Betaseron, BAY86-5046)","otherNames":[]},{"name":"Interferon beta-1b (Betaseron, BAY86-5046)","otherNames":[]},{"name":"Interferon beta-1b (Betaseron, BAY86-5046)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completion of the BEYOND study 306440 as scheduled\n* Relapsing multiple sclerosis\n* Medical assessment by the investigator that there is no objection to the patient's participation in this trial considering the medical experience from study 306440. Special attention should be given to laboratory abnormalities and clinically relevant liver, renal and bone-marrow dysfunction.\n* Females of child-bearing potential:\n\n  * Agreement to practice adequate contraception methods and\n  * Negative pregnancy test and\n  * No lactation\n* Written informed consent\n\nExclusion Criteria:\n\n* Serious or acute heart diseases\n* History of severe depression or suicide attempt\n* Epilepsy not adequately controlled by treatment\n* Known allergy to IFNs, to human albumin or to mannitol\n* Medical, psychiatric or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Flu-like-syndrome","description":"The variable \"Flu-like-syndrome\" will consist of a combination of MedDRA terms (Preferred Terms and Lower Level Terms) indicative for this condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":null},{"groupId":"OG001","value":"15.8","spread":null},{"groupId":"OG002","value":"31.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Injection-site Reactions","description":"The variable \"Injection-site reactions\" will consist of a combination of MedDRA terms (Preferred Terms only) indicative for this condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null},{"groupId":"OG001","value":"26.2","spread":null},{"groupId":"OG002","value":"31.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Liver Enzyme Elevations","description":"The variable \"Liver enzyme elevations\" will consist of a combination of MedDRA terms (Preferred Terms only) indicative for this condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"1.4","spread":null},{"groupId":"OG002","value":"3.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"1.7","spread":null},{"groupId":"OG002","value":"4.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Hematological Abnormalities","description":"The variable \"Hematological abnormalities\" will consist of a combination of MedDRA terms (Preferred Terms only) indicative for this condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"0.2","spread":null},{"groupId":"OG002","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Neutralizing Antibody Titer to IFNB-1b of Different Cut-off Values","description":"Serum samples of about 8 mL for analysis of neutralizing antibodies (NAbs) to interferon (IFN) beta-1b were drawn at Baseline, Week 26 and the EOS visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":null},{"groupId":"OG001","value":"21.7","spread":null},{"groupId":"OG002","value":"16.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"12.4","spread":null},{"groupId":"OG002","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.8","spread":null},{"groupId":"OG001","value":"6.1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":586},"commonTop":["Fatigue","Headache","Influenza like illness","Injection site reaction","Injection site erythema"]}}}